TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25465451
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral dialog of the surgical risks
Study: 23419912
Drug: Non‐therapeutic dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐therapeutic dose of intermittent ultrasound
Study: 19002337
Drug: Light-fractionated aminolaevulinic
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light-fractionated aminolaevulinic acid photodynamic therapy (PDT)
Study: 16198776
Drug: Continuous-dose terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-dose terbinafine (250 mg daily for 3 months)
Study: 16198776
Drug: Pulse-dose terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse-dose terbinafine (500 mg daily for 1 week per month for 3 months)
Study: 1011909
Drug: Modified lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified lateral subcutaneous sphincterotomy
Study: 31331757
Drug: IP cefepime
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP cefepime monotherapy, 1g/d
Study: 31331757
Drug: IP combination
Normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP combination of cefazolin and ceftazidime, 1g/d
Study: 25449505
Drug: eGFR group-III
Normalized name: Corticosteroids, potent (group III)
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR group-III (≤ 59 ml/min/1.73 m²)
Study: 17398308
Drug: 1800 mg
Normalized name: glycerin 1800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg of eicosapentaenoic acid (EPA) daily with statin (EPA group; n=9326)
Study: 17398308
Drug: EPA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA treatment in patients with a history of coronary artery disease
Study: 17398308
Drug: EPA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA treatment in patients with no history of coronary artery disease
Study: 10475405
Drug: Nitecapone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitecapone (50 microM solution in Plegisol)
Study: 8745384
Drug: Valproic acid,
Normalized name: Valproic Acid, 250 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproic acid, 125 mg twice daily
Study: 27592224
Drug: Optimum medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimum medical treatment for heart failure alone (Control group)
Study: 25283504
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant urate oxidase (uricase) at doses of 0.1, 0.2, and 0.3 mg/kg; multiple doses of 0.2 mg·kg(‐1)·d(‐1) for 7 days
Study: 25283504
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant urate oxidase (uricase)
Study: 21119098
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care program (5 individual counseling sessions by a pharmacist over 1 year)
Study: 21119098
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Pharmaceutical care and Usual care)
Study: 15877788
Drug: Octreotide 0.1
Normalized name: octreotide 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 0.1 mg subcutaneously at the time of operation and 3x/d thereafter until post-operative day 7
Study: 23890768
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m² on day 1 plus erlotinib 150 mg daily on days 2-14
Study: 23890768
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m² on day 1
Study: 17333123
Drug: Manual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual physical therapy (Group 2)
Study: 15144242
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding without NG tube (Group B)
Study: 12536650
Drug: Nylestriol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nylestriol (2 mg)
Study: 10545723
Drug: Bionormalizer 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bionormalizer 9 g at bedtime and 3 h prior examination
Study: 10545723
Drug: Flavored sugar
Normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavored sugar 9 g as placebo
Study: 2328301
Drug: Austyn (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Austyn (sustained-release theophylline capsule) with food
Study: 2328301
Drug: Austyn (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Austyn (sustained-release theophylline capsule) fasting
Study: 2328301
Drug: Elixophyllin elixir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elixophyllin elixir (reference product) fasting
Study: 2328301
Drug: Austyn capsules
Normalized name: STOMA CAP STYLE E AUSTIN #838234001261
Approvals — FDA: no, EMA: no, PMDA: no
Description: Austyn capsules (multiple dosing)
Study: 2328301
Drug: Theo-Dur (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theo-Dur (sustained-release tablet)
Study: 2328301
Drug: Austyn (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Austyn (sustained-release capsule)
Study: 7211858
Drug: Pfi‐Lithium (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfi‐Lithium (300 mg)
Study: 7211858
Drug: Eskalith (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eskalith (300 mg)
Study: 27906684
Drug: PF-03084014 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-03084014 100 mg twice daily / docetaxel 75 mg/m2
Study: 26115087
Drug: High-energy-dense preload
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy-dense preload (94 kcal/100 g)
Study: 26115087
Drug: Low-energy-dense preload
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy-dense preload (53 kcal/100 g)
Study: 23981966
Drug: Pemetrexed plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed plus carboplatin with concurrent radiation therapy (PCb)
Study: 23981966
Drug: Pemetrexed plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed plus cisplatin with concurrent radiation therapy (PC)
Study: 17716376
Drug: 8-week lifestyle
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week lifestyle modification program based on the Choose to Move program; includes audio-taped activity instructions and educational package delivered in weekly home visits.
Study: 11476107
Drug: Stanozolol 2
Normalized name: stanozolol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stanozolol 2 mg twice daily along with cetrizine 10 mg daily
Study: 11476107
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets twice daily along with cetrizine 10 mg daily
Study: 9433364
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 16 mg inhaled daily for 6 weeks
Study: 3303001
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide (8 mg/kg over 7 hours) and chlorpromazine (50 mg orally)
Study: 3303001
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose of metoclopramide (6 mg/kg over 7 hours) and chlorpromazine (50 mg orally)
Study: 11698315
Drug: i.v. metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. metoclopramide 10 mg
Study: 2334619
Drug: i.m. metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. metoclopramide 10 mg
Study: 2334619
Drug: oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral diazepam 10 mg
Study: 4027102
Drug: i.m. morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. morphine 10 mg
Study: 4416311
Drug: Diazepam 5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5‐10 mg supplied into the oxygenator
Study: 29087880
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg before surgery, then three times daily for 6 doses
Study: 23281174
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and Alcohol
Study: 22452896
Drug: Afatinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (50 mg per day)
Study: 19413595
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) infusion (0.5 to 2 microg/kg per min for 30 min)
Study: 19413595
Drug: Oral extended-release
Normalized name: Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral extended-release isosorbide mononitrate (120 mg)
Study: 19413595
Drug: Pentaerythritol tetranitrate
Normalized name: Pentaerythritol tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaerythritol tetranitrate (160 mg)
Study: 12439917
Drug: Intraperitoneal thermochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal thermochemotherapy and intraperitoneal IL-2 immunotherapy (10 million IU in 500 ml 0.9% sodium chloride daily for 10 times)
Study: 9817305
Drug: Tacrolimus and
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus and prednisone with mycophenolate mofetil (2 gm daily)
Study: 8929935
Drug: Comprehensive array
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comprehensive array of substance-abuse treatment services
Study: 328327
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg HBB
Study: 328327
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg HBB
Study: 28167511
Drug: Monthly financial
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly financial incentives contingent on observed breastfeeding for 6 months (amount increased from $20 to $70, total possible $270)
Study: 23415672
Drug: Sequential systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential systemic carboplatin and paclitaxel followed by percutaneous irradiation
Study: 21819530
Drug: SQV/r 2000/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV/r 2000/100 mg
Study: 21819530
Drug: ATV/r 300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV/r 300/100 mg
Study: 17322178
Drug: Pharmacotherapy (including
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (including disulfiram, naltrexone, acamprosate)
Study: 17322178
Drug: Monthly, extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly, extended-release formulation of naltrexone
Study: 11302295
Drug: Psychosocial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial therapy
Study: 11601765
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Fourth generation dentine‐bonding agent and composite restoration (control)
Study: 8080372
Drug: Conservative, nonexcisional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative, nonexcisional therapy (meticulous hair control by natal cleft shaving, improved perineal hygiene, limited lateral incision and drainage for abscess)
Study: 2609140
Drug: Trichlormethiazide 4
Normalized name: trichlormethiazide 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichlormethiazide 4 mg/d
Study: 2609140
Drug: Trichlormethiazide and
Normalized name: trichlormethiazide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichlormethiazide and amiloride 2 mg/d each
Study: 4947491
Drug: Various drug
Normalized name: VARIOUS DRUG CLASSES IN ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various drug combinations and dosages; treatment duration and rhythms; drug toxicity prevention; home treatment vs. sanatorium treatment; routine home visiting; pretreatment sensitivity tests; short (6-month) intensive courses vs. long-term (18-month) standard courses
Study: 31004286
Drug: 0.5% carbomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% carbomer 980 gel
Study: 27381253
Drug: 24 IU
Normalized name: Nasopro 24
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 24 IU of intranasal OXT
Study: 18485261
Drug: Duloxetine 20
Normalized name: duloxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 20 mg
Study: 18485261
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR 75-225 mg
Study: 17848625
Drug: Higher aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher aspirin doses (162 mg and 325 mg)
Study: 11679505
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (800 microg)
Study: 8205582
Drug: Rembrandt Gel
Normalized name: Rembrandt
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rembrandt Gel Plus
Study: 4619059
Drug: Mefloquine hydrochloride
Normalized name: Mefloquine Hydrochloride
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefloquine hydrochloride (WR 142490), single dose
Study: 30260740
Drug: EPA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-rich fish oil (600 mg EPA and 260 mg DHA per day for 8 weeks)
Study: 28448329
Drug: Educational program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational program (individualized education session, self-care manual, and weekly phone calls)
Study: 21106710
Drug: Alendronate (ALN)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate (ALN) 5 mg/d for children < 40 kg and 10 mg/d for children ≥ 40 kg
Study: 18210952
Drug: High compression
Normalized name: BANDAGE,HIGH COMPRESSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: High compression therapy plus amelogenin
Study: 14667945
Drug: Increased M-L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased M-L motion of the COM during obstacle crossing
Study: 3569028
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate 900 mg iv q8h (treatment C)
Study: 3569028
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate 600 mg iv q6h (treatment A)
Study: 3569028
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate 600 mg iv q8h (treatment B)
Study: 24893766
Drug: KYNA injection
Normalized name: Kynamro
DrugBank: Mipomersen (DB05528)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KYNA injection
Study: 20545244
Drug: Agua das
Normalized name: agua
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agua das Pedras (sodium-rich carbonated mineral water), 500 ml/day for 7 weeks
Study: 20545244
Drug: Agua Vitalis
Normalized name: agua
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agua Vitalis (control), 500 ml/day for 7 weeks
Study: 16278522
Drug: Other antihypertensive
Normalized name: Other antihypertensives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antihypertensive drug classes
Study: 12412675
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg, once a day)
Study: 8547195
Drug: Intensive follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive follow-up group (6 monthly chest X-rays and bone scans)
Study: 2403473
Drug: Computer-administered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-administered cognitive-behavioral treatment
Study: 2403473
Drug: Therapist-administered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-administered cognitive-behavioral treatment
Study: 26189253
Drug: Intensity-Modulated Radiotherapy
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity-Modulated Radiotherapy (IMRT) with concurrent chemotherapy (nedaplatin 30 mg/m2 weekly for six cycles)
Study: 26189253
Drug: Three-Dimensional Conformal
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-Dimensional Conformal Radiotherapy (3D CRT) with concurrent chemotherapy (nedaplatin 30 mg/m2 weekly for six cycles)
Study: 23656836
Drug: Incentive strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentive strategy promoting adherence to laboratory confirmation of malaria before treatment at facility-level
Study: 19089321
Drug: Loratadine/Montelukast (L/M)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine/Montelukast (L/M) 10 mg/10 mg
Study: 11535842
Drug: Oral diltiazem
Normalized name: diltiazem Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diltiazem (60 mg, twice daily for up to eight weeks)
Study: 11535842
Drug: Topical diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diltiazem (2 percent gel, twice daily for up to eight weeks)
Study: 8394651
Drug: MCPP (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCPP (0.35 mg/kg p.o.)
Study: 8394651
Drug: Clozapine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (up to 600 mg/day for 5 weeks)
Study: 23363371
Drug: Wii Fit
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Wii Fit intervention (10 min thrice weekly for 1 month)
Study: 18656328
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of enalapril plus 0.4 mg of folic acid (low‐FA group)
Study: 18656328
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of enalapril plus 0.8 mg of folic acid (high‐FA group)
Study: 18656328
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of enalapril (control group)
Study: 16301338
Drug: Seated 1‐G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seated 1‐G position (reference)
Study: 8711491
Drug: Intra-arterial thrombolysis
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial thrombolysis (IAT) with low-dose recombinant tissue-type plasminogen activator (rt-PA) (0.02 to 0.05 mg/h)
Study: 1509913
Drug: Monotherapy (orchiectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (orchiectomy only)
Study: 6871626
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol and a balanced electrolyte solution (PEG + E)
Study: 30278479
Drug: Biliary drainage
Normalized name: PLEURX DRAINAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biliary drainage (interventional therapy)
Study: 22004457
Drug: Mosapride 5
Normalized name: mosapride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride 5 mg tid
Study: 22004457
Drug: Teprenone 50
Normalized name: teprenone
DrugBank: Teprenone (DB15955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teprenone 50 mg tid
Study: 18704618
Drug: Pre-emptive Bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive Bupivacaine (PBU) - 10 ml 0.5% Bupivacaine to port sites before skin incision and another 10 ml to the preperitoneal space immediately after the creation of a first working port.
Study: 18704618
Drug: Control (CO)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (CO) - Saline injection instead of Bupivacaine.
Study: 15367189
Drug: 0.2% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% CHX spray (test group)
Study: 9555822
Drug: 0.025% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% tretinoin gel containing polyolprepolymer‐2
Study: 9555822
Drug: 0.025% commercially‐available
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% commercially‐available tretinoin gel
Study: 9555822
Drug: Both active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both active medications
Study: 8275406
Drug: DPT vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPT vaccine (group A, 99 children)
Study: 8275406
Drug: Intramuscular pertussis
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular pertussis vaccine (group A, 99 children)
Study: 8275406
Drug: DT vaccine
Normalized name: Diphtheria Toxoid, Adsorbed/Tetanus Toxoid Intramuscular Suspension [DT VACCINE ADSORBED PEDIATRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DT vaccine (group B, 101 children)
Study: 8275406
Drug: Intramuscular pertussis
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular pertussis vaccine
Study: 2542197
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy alone (RT) (50 Gy large field and 10 Gy boost)
Study: 2542197
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy combined with misonidazole (400 mg/m2 2‐4 hr prior to RT daily for 5‐6 weeks)
Study: 29733400
Drug: ILO once
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ILO once monthly (group B)
Study: 25638597
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day whey protein-supplemented beverage
Study: 21040143
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (Gamunex)
Study: 16550750
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (any approved phosphate binder)
Study: 8783327
Drug: NSAID‐morphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID‐morphine treatment
Study: 1479003
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg D‐Trp‐6‐luteinizing hormone-releasing hormone (LHRH)
Study: 1479003
Drug: 1.87 mg
Normalized name: proline 1.87 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.87 mg D‐Trp‐6‐luteinizing hormone-releasing hormone (LHRH)